GlassScriptPhysician profile
Elvira Rios
NPI 1285788307
$2,666.06
in general payments reported to CMS, 2019-2025
24 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2.49 · 2021: $109 · 2022: $125 · 2023: $465 · 2024: $719 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.09 | 2023-2025 | Ubrelvy, Vraylar, Viberzi |
| Amgen INC. | $451.46 | 2024-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $415.88 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $242.35 | 2021-2024 | Airsupra |
| Lilly USA, LLC | $178.07 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $94.11 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $75.86 | 2024-2025 | Veozah |
| Gilead Sciences, INC. | $69.51 | 2023 | Epclusa |
| Pfizer INC. | $54.28 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $47.31 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.95 | 2025 | Caplyta |
| Abbott Laboratories | $40.54 | 2024-2025 | Freestyle Libre 3 |
| Pulmonx Corporation | $39.69 | 2023 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $35.80 | 2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $28.45 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.95 | 2023-2024 | |
| Sanofi Pasteur INC. | $24.22 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.49 | 2025 | |
| Axsome Therapeutics, INC. | $18.52 | 2025 | Auvelity |
| Boston Scientific Corporation | $16.88 | 2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $13.79 | 2025 | Gardasil 9, M-M-R II, Capvaxive |
| Phathom Pharmaceuticals, INC. | $13.76 | 2025 | Voquezna |
| Travere Therapeutics, INC. | $2.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvira Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.